Volume | 2,386,469 |
|
|||||
News | - | ||||||
Day High | 67.81 | Low High |
|||||
Day Low | 67.215 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
67.48 | 67.215 | 67.81 | 67.24 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
26,800 | 2,386,469 | $ 67.55 | $ 161,214,878 | - | 65.275 - 81.435 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:00:22 | 100 | $ 67.225 | USD |
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 141.09B | 2.10B | 2.10B | $ 46.16B | $ 6.40B | 2.95 | 22.60 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ 2.19 | 3.43% | 04/06/23 | -258.22k | 0.30% |
Bristol Myers Squibb News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 66.30 | 67.81 | 65.76 | 66.89 | 12,397,344 | 0.925 | 1.4% |
1 Month | 71.27 | 71.98 | 65.275 | 68.01 | 8,244,163 | -4.05 | -5.68% |
3 Months | 73.18 | 75.18 | 65.275 | 70.88 | 8,252,786 | -5.96 | -8.14% |
6 Months | 69.74 | 81.435 | 65.275 | 73.20 | 8,910,861 | -2.52 | -3.61% |
1 Year | 71.48 | 81.435 | 65.275 | 74.01 | 10,654,078 | -4.26 | -5.95% |
3 Years | 47.22 | 81.435 | 45.76 | 65.55 | 11,596,854 | 20.01 | 42.37% |
5 Years | 66.54 | 81.435 | 41.19 | 60.32 | 11,946,869 | 0.685 | 1.03% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |